{
  "reportDate": "2023-12-10",
  "sampleId": "GENOMICS-001",
  "sampleType": "Tumor tissue",
  "sequencingPlatform": "Illumina NovaSeq",
  "panelName": "Comprehensive Cancer Panel",
  "tumorMutationalBurden": 8.2,
  "microsatelliteStatus": "MSS",
  "mutationProfile": [
    {
      "gene": "TP53",
      "chromosome": "17",
      "position": "7577539",
      "variant": "p.R273H",
      "variantType": "missense",
      "vaf": 0.42,
      "interpretation": "Pathogenic",
      "cosmicId": "COSM10663",
      "clinicalSignificance": "Loss of tumor suppressor function",
      "therapeuticImplications": "Associated with resistance to conventional chemotherapy"
    },
    {
      "gene": "CDKN2A",
      "chromosome": "9",
      "position": "21970916",
      "variant": "p.R58*",
      "variantType": "nonsense",
      "vaf": 0.38,
      "interpretation": "Pathogenic",
      "cosmicId": "COSM12345",
      "clinicalSignificance": "Loss of cell cycle control",
      "therapeuticImplications": "Potential target for CDK4/6 inhibitors"
    },
    {
      "gene": "PIK3CA",
      "chromosome": "3",
      "position": "178952085",
      "variant": "p.H1047R",
      "variantType": "missense",
      "vaf": 0.28,
      "interpretation": "Likely Pathogenic",
      "cosmicId": "COSM775",
      "clinicalSignificance": "PI3K pathway activation",
      "therapeuticImplications": "Potential target for PI3K inhibitors"
    }
  ],
  "copyNumberVariations": [
    {
      "gene": "EGFR",
      "copyNumber": 2.1,
      "interpretation": "Normal"
    },
    {
      "gene": "MYC",
      "copyNumber": 3.8,
      "interpretation": "Amplified"
    }
  ],
  "immuneMarkers": {
    "pdl1Expression": "40%",
    "cd8TilDensity": "High",
    "mismatchRepairStatus": "Proficient"
  },
  "recommendations": [
    "Consider platinum-based chemotherapy as first-line treatment",
    "TP53 mutation may confer resistance to conventional therapy",
    "High PD-L1 expression suggests potential benefit from immunotherapy",
    "PIK3CA mutation - consider clinical trial with PI3K inhibitors"
  ]
}